Replies to post #121690 on Amarantus Bioscience Holdings Inc (AMBS)

[JJAAMMAANN]

Not sure I am connecting all the dots either...
May be something in the works to force Roche to buy all the diagnostics instead of just the Cancer test.
If his speaking was the truth, his test is far superior than the one the Roche already owns. Maybe Roche will buy out the company, and in the process issuing more shares to AMBS will force Roche to pay more for the company on a Per share value?
Just a thought.

Roche has paid tons for other companies shares.

After eight months of resistance, Genentech agreed Thursday to a deal in which Roche will pay $95 a share for the 44 percent of Genentech that it does not own.

The new price is higher than the $89 Roche offered in July and a bit higher than its offer last Friday of $93. While Genentech directors initially asked for $112, they came to realize that price was unrealistic in the face of sharply falling world stock markets, according to a regulatory filing by Genentech.

http://www.nytimes.com/2009/03/13/business/worldbusiness/13drugs.html

In My Own Personal Opinion Of Course!
Long AMBS!